<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00206960</url>
  </required_header>
  <id_info>
    <org_study_id>363002</org_study_id>
    <secondary_id>KF 01-078/97</secondary_id>
    <secondary_id>KF 01-012/98</secondary_id>
    <secondary_id>KF 11-057/99</secondary_id>
    <nct_id>NCT00206960</nct_id>
  </id_info>
  <brief_title>Dopaminergic, Functional, Structural, and Cognitive Disturbances in First-episode Schizophrenia</brief_title>
  <official_title>Effects of Classical and Atypical Antipsychotics on Dopamine Receptor Binding of 123I-epidepride, Cognition, Startle Response and Extrapyramidal Side-effects in Drug-naive First-episode Schizophrenic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Birte Glenthoj</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Glostrup University Hospital, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Danish Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen Hospital Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen-Cilag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Novo Nordic Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We wanted to compare dopamine D2 receptor activity, brain structure, brain function, sensory
      gating and cognition in neuroleptic-naive schizophrenic patients and matched healthy
      controls. Additionally, we wanted to examine the effects of 3 months of treatment with either
      low doses of a typical or an atypical antipsychotic compound on the same functions. The
      hypotheses were that schizophrenic patients suffered from disturbances in brain function and
      structure, information processing, and extrastriatal D2 receptor activity, and that these
      disturbances would be related to each other and to psychopathology. Additionally, we expected
      the atypical compound to have an effect on some of the disturbances in information
      processing, and that the atypical compound - in contrast to the typical drug - would show
      extrastriatal over striatal selectivity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      31 neuroleptic-naive schizophrenic patients and 25 matched controls were recruited from the
      greater Copenhagen area. The patients were randomized to treatment with either low doses of
      the typical antipsychotic compound, zuclopenthixol, or the atypical drug, risperidone.
      Patients and controls were examined at base-line and patients were re-examined after 3 months
      of treatment.The study has resulted in two finish Ph.D. theses (Torben Mackeprang and
      Birgitte Fagerlund).

      The data has in part been published in:

      Mackeprang T, Tjelle Kristiansen K, Glenthoj B. Prepulse inhibition of the startle response
      in drug-naïve, first-episode schizophrenic patients before and after 3 months of treatment
      with a typical or an atypical antipsychotic drug. Biological Psychiatry 2002; 52(9): 863-873.

      and

      Fagerlund B, Mackeprang T, Gade A, Hemmingsen R, Glenthoj BY. Effects of Low-Dose Risperidone
      and Low-Dose Zuclopenthixol on Cognitive Functions in First-Episode Drug-Naïve Schizophrenic
      Patients. CNS Spectr. 2004; 9: 364-74.

      and

      Glenthoj BY, Mackeprang T, Svarer C, Rasmussen H, Pinborg L, Friberg L, Baaré W, Hemmingsen
      R, Videbæk C. Frontal dopamine D2/3 receptor binding in drug-naïve first-episode
      schizophrenic patients correlates with positive psychotic symptoms and gender. Biological
      Psychiatry 2006; in press. Mar 30; [Epub ahead of print]. PMID: 16784819 [PubMed - as
      supplied by publisher].

      We are at present conducting a five-year follow-up study of the same cohort of patients and
      controls and plan a ten-year follow-up as well. The follow-up studies focus on brain
      structure (MRI), brain function, information processing, and psychopathology. We will
      correlate changes in structure and function to treatment, but no interventions
      (pharmacological or otherwise) are planned.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1998</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All examinations are done at baseline (patients and controls). In the patient group, they are repeated after 3 months of treatment</measure>
    <time_frame>prospective</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PANSS</measure>
    <time_frame>prospective</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SANS</measure>
    <time_frame>prospective</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SAPS</measure>
    <time_frame>prospective</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MRI</measure>
    <time_frame>prospective</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fMRI</measure>
    <time_frame>prospective</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>startle response</measure>
    <time_frame>prospective</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PrePulse Inhibition of the startle response (PPI)</measure>
    <time_frame>prospective</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognition</measure>
    <time_frame>prospective</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The cognitive test battery comprised tests from the Cambridge Neuropsychological Test Automated Battery (CANTAB) as well as paper-and-pencil cognitive tests.</measure>
    <time_frame>prospective</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zuclopenthixol</intervention_name>
    <description>Patients will be administered zuclopenthixol orally in doses between 4 -24 mg/day, depending on an effective reduction of symptoms</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Cisordinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risperidone</intervention_name>
    <description>Patients will be administered risperidone orally in doses between 1-6 mg/day, depending on an effective reduction of symptoms</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Risperdal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For patients: Clinical diagnosis of schizophrenia.

          -  The controls were matched to the patients.

        Exclusion Criteria:

          -  Patients: Previous antipsychotic treatment, patients who were compulsorily
             hospitalised or deemed in acute need of medication, mental retardation

          -  Controls: psychiatric diagnosis, psychiatric diagnosis in first-degree relatives, drug
             abuse, mental retardation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Birte Glenthoj, MD, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>University of Copenhagen, Psychiatric Center Glostrup, Ndr. Ringvej, DK-2600 Glostrup, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Nuclear Medicine, University of Copenhagen, Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen NV</city>
        <zip>DK-2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Copenhagen, Dept. F, Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen NV</city>
        <zip>DK-2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Copenhagen, Dept. of Psychiatry E, Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen NV</city>
        <zip>DK-2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurobiology Research Unit, University of Copenhagen, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup</name>
      <address>
        <city>Glostrup</city>
        <zip>DK-2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danish Research Center for Magnetic Resonance Imaging, Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>DK-2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <results_reference>
    <citation>Mackeprang T, Kristiansen KT, Glenthoj BY. Effects of antipsychotics on prepulse inhibition of the startle response in drug-naïve schizophrenic patients. Biol Psychiatry. 2002 Nov 1;52(9):863-73.</citation>
    <PMID>12399139</PMID>
  </results_reference>
  <results_reference>
    <citation>Fagerlund B, Mackeprang T, Gade A, Glenthøj BY. Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients. CNS Spectr. 2004 May;9(5):364-74.</citation>
    <PMID>15115949</PMID>
  </results_reference>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>September 16, 2011</last_update_submitted>
  <last_update_submitted_qc>September 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Birte Glenthoj</investigator_full_name>
    <investigator_title>Professor of Psychopharmacology and Neuropsychiatry, Danish Center for Neuropsychiatric Schizophrenia Research</investigator_title>
  </responsible_party>
  <keyword>drug-naive</keyword>
  <keyword>epidepride</keyword>
  <keyword>single tomography</keyword>
  <keyword>D2 receptor</keyword>
  <keyword>information processing</keyword>
  <keyword>PPI</keyword>
  <keyword>antipsychotic treatment</keyword>
  <keyword>MRI</keyword>
  <keyword>fMRI</keyword>
  <keyword>cognitive disturbances</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Clopenthixol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

